A detailed history of Ubs Oconnor LLC transactions in Ovid Therapeutics Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 288,290 shares of OVID stock, worth $340,182. This represents 0.01% of its overall portfolio holdings.

Number of Shares
288,290
Holding current value
$340,182
% of portfolio
0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$0.7 - $3.34 $20,153 - $96,158
28,790 Added 11.09%
288,290 $221,000
Q1 2024

May 15, 2024

BUY
$2.72 - $4.04 $312,800 - $464,600
115,000 Added 79.58%
259,500 $791,000
Q4 2023

Feb 14, 2024

SELL
$2.98 - $3.78 $16,390 - $20,790
-5,500 Reduced 3.67%
144,500 $465,000
Q3 2023

Nov 14, 2023

BUY
$3.23 - $3.97 $64,600 - $79,400
20,000 Added 15.38%
150,000 $576,000
Q2 2023

Aug 14, 2023

BUY
$2.53 - $3.89 $328,900 - $505,700
130,000 New
130,000 $426 Million

Others Institutions Holding OVID

About Ovid Therapeutics Inc.


  • Ticker OVID
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,419,400
  • Market Cap $83.1M
  • Description
  • Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...
More about OVID
Track This Portfolio

Track Ubs Oconnor LLC Portfolio

Follow Ubs Oconnor LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.